The burden of colorectal cancer: prevention, treatment and quality of services

Kanavos, Panos; Schurer, Willemien

doi:10.1007/s10198-009-0200-3

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though cancer causes a large economic burden, only a few countries have actually estimated how large these costs really are. A previous supplement of this journal, which focused on colorectal cancer and its burden in a number of OECD countries, highlights the need for detailed countryspecific colorectal cancer costing studies [8,9].…”

Section: Introductionmentioning

confidence: 99%

Cost of care for colorectal cancer in Ireland: a health care payer perspective

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Cost of care for colorectal cancer in Ireland: a health care payer perspective

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Options include stool-based blood tests, faecal immunochemical tests, endoscopic methods and colonoscopy, with CT colonography and analysis of biomarkers in the stool, blood, or breath under development [ 68 , 69 ]. A 2003 EU Council recommendation included national CRC screening, and a 2007 declaration re-iterated the need for more outstanding official support for CRC screening and standardisation of practices across Europe [ 70 , 71 ]. Organised screening programs exist in Finland, France, Slovenia, the Netherlands and the United Kingdom.…”

Section: Resultsmentioning

confidence: 99%

“…Current guidelines from the National Institute for Health and Care Excellence (NICE) and medical societies include details on patient-centred care, treatment access, multidisciplinary teams, diagnosis, surgery, radiotherapy, chemotherapy, surveillance, recurrence, and palliative care. Provision is suitable for data collection, awareness, choice of treatment and endoscopy centres and national cancer plans are good, but NICE should work faster, guidelines should be more precise and more recent, and regional variations in care should be overcome [ 71 , 81 ].…”

Section: Resultsmentioning

confidence: 99%

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

et al. 2022

View full text Add to dashboard Cite

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices—such as population-level screening for lung cancer—are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.

show abstract

“…This 5-FU/FA combination offered survival benefits over best supportive care and became established as standard therapy for the treatment of colorectal cancer. Additionally, in recent years several important pharmaceutical advances have helped to prolong survival for patients with late stage disease from approximately 5 months to over 20 months (7), with several agents found to deliver benefits either in combination with 5-FU/FA or as second- or third-line options. These advancements have included the development of cytotoxic agents (irinotecan and oxaliplatin), oral analogues of fluorouracil (such as capecitabine), and targeted biologics (bevacizumab, cetuximab, panitumumab, regorafenib, and aflibercept).…”

Section: Background On Pharmaceutical Developments In Breast Cancer Amentioning

confidence: 99%

A Review of Health Technology Appraisals: Case Studies in Oncology

Shah

Mestre-Ferrandiz

Towse

et al. 2012

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Pharmaceutical manufacturers, regulators, patients, providers, and payers all have a shared interest in improving health outcomes for patients with cancer. Each plays an important role in helping to achieve this common goal. Pharmaceutical manufacturers seek to develop new medicines that are supported by robust and clinically meaningful evidence of their safety, efficacy, and effectiveness. Regulators authorize these medicines based on evaluations of their safety and efficacy. Patients and providers together make treatment decisions and desire access to the most effective treatment options. Payers appraise new medicines with the goal of ensuring access to those medicines that constitute efficient uses of healthcare expenditure. Profits generated from the sale of the medicines provide a return to the manufacturer, which helps to drive continued research and development in an effort to improve patient health outcomes and societal well-being. Many payers have initiated health technology assessment (HTA) activities to inform decision making in light of the rising costs of health care. Given the financial constraints imposed as a result of the global economic crisis, HTAs are likely to become increasingly important as payers seek value for money solutions to major health problems. Successful collaboration and aligning incentives across stakeholders is critical to ensuring that patients are able to access the most effective medicines.

show abstract

The burden of colorectal cancer: prevention, treatment and quality of services

Abstract: I11, I12, I18,

Cited by 4 publications

References 3 publications

Cost of care for colorectal cancer in Ireland: a health care payer perspective

Cost of care for colorectal cancer in Ireland: a health care payer perspective

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

A Review of Health Technology Appraisals: Case Studies in Oncology

Contact Info

Product

Resources

About